supplementary table 2.docx (22.44 kB)

Supplementary table 2.docx: A Phase I trial of talazoparib in patients witha dvanced hematologic malignancies

dataset

posted on 2021-10-23, 12:03 authored by Ajay K Gopal, Rakesh Popat, Ryan J Mattison, Tobias Menne, Adrian Bloor, Terry Gaymes, Asim Khwaja, Mark Juckett, Ying Chen, Matthew J Cotter, Ghulam J Mufti

Supplementary Table 2. Exposure to talazoparib (safety population).

Funding

This study was sponsored by Biomarin/Medivation, which was acquired by Pfizer Inc. in September 2016 (grant number not applicable).

History

Usage metrics

Keywords

Poly(ADP-ribose) polymerase inhibition talazoparib hematologic malignancy DNA damage response BRCA1/2 mutations Hematology

Licence

CC BY-NC-ND 4.0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM